Trial · NCT06940895
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
NCT06940895, Phase 2, Completed, Narrows Institute for Biomedical Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans. Trials, record NCT06940895. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06940895
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
- NCT number
- NCT06940895
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Narrows Institute for Biomedical Research
- Conditions
- Acanthosis Nigricans
- Interventions
- Sirolimus 0.2%
- First posted
- 2025-04-23
- Last updated
- 2025-11-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in hyperpigmentation in acanthosis nigricans lesions | From enrollment to end of treatment at 12 weeks | Improvement in the Melanin(M) index from baseline to 12 weeks of treatment. The M index is positively correlated with a darker skin color and ranges from 0-999. |
| Secondary | Improvement in hyperpigmentation and skin texture in acanthosis nigricans lesions | Baseline to weeks 4, 8, and 12 | Improvement in the ANSC (Acanthosis Nigricans Scoring Chart) from baseline (Day 0) to Visit 2 (Week 4), Visit 3 (Week 8) and Visit 4 (Week 12). ANSC is scored on a scale of 1 to 8 for skin color and 1 to 6 for skin texture. These scores are then combined for a total ANSC score ranging from 2 to 14. |
| Secondary | Improvement in the Investigators Global Evaluation (IGE) scale and Patient Global Evaluation (PGE) scale | Baseline to weeks 4, 8, and 12 | IGE and PGE are both scored on a 0 to 6 scale: 0 signifies "clear," 1 indicates "almost clear or \> 90% improvement," 2 represents "marked improvement or 75% improvement," 3 denotes "moderate improvement or 50% improvement," 4 signifies "mild improvement or 25% improvement," 5 indicates "no change," and 6 means "worsening." |
| Secondary | Improvement in the Dermatology Quality of Life (DLQI) scale | From enrollment to end of treatment at 12 weeks | The DLQI ranges from 0 to 30 with higher scores denoting worse quality of life. |
| Secondary | Assessment of patient satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM) | Week 12 | Assessment of patient satisfaction using the treatment satisfaction questionnaire for medication |
| Secondary | Digital photography with a TwinFlash RL Clinical Camera to depict clinical improvement of acanthosis nigricans. | Baseline to weeks 4, 8, and 12 | Digital photography with a TwinFlash RL Clinical Camera to depict clinical improvement of AN |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06940895
GET https://conductscience.org/api/trials/v1/NCT06940895/registered